XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues:        
Total revenues $ 7,421 $ 6,577 $ 20,061 $ 17,268
Costs and expenses:        
Cost of goods sold 1,223 1,141 3,974 3,174
Research and development expenses 1,147 1,158 3,336 3,461
Acquired in-process research and development expenses 19 1,171 177 5,792
Selling, general and administrative expenses 1,190 1,106 3,596 3,421
Total costs and expenses 3,579 4,576 11,083 15,848
Income from operations 3,842 2,001 8,978 1,420
Interest expense (250) (236) (763) (717)
Other income (expense), net (154) (940) (696) (848)
Income (loss) before income taxes 3,438 825 7,519 (145)
Income tax expense (852) (472) (1,694) (1,310)
Net income (loss) 2,586 353 5,825 (1,455)
Net loss attributable to noncontrolling interest 6 7 18 27
Net income (loss) attributable to Gilead $ 2,592 $ 360 $ 5,843 $ (1,428)
Net income (loss) per share attributable to Gilead common stockholders - basic (in dollars per share) $ 2.06 $ 0.29 $ 4.65 $ (1.14)
Shares used in per share calculation - basic (in shares) 1,256 1,255 1,256 1,257
Net income (loss) per share attributable to Gilead common stockholders - diluted (in dollars per share) $ 2.05 $ 0.29 $ 4.63 $ (1.14)
Shares used in per share calculation - diluted (in shares) 1,262 1,261 1,262 1,257
Product sales        
Revenues:        
Total revenues $ 7,356 $ 6,493 $ 19,848 $ 17,027
Royalty, contract and other revenues        
Revenues:        
Total revenues $ 65 $ 84 $ 213 $ 241